July 2016

New Product - Xofigo

Xofigo (radium (223Ra) dichloride) is a therapeutic alpha particle emitting pharmaceutical with targeted anti‑tumour effect on bone metastases. The active moiety of Xofigo is the isotope Ra‑223 (as Ra‑223 dichloride), which mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters (80 keV/micrometre) leads to a high frequency of double strand DNA breaks in adjacent cells, resulting in a potent and localised anti-tumour effect. Xofigo is indicated for the treatment of castration‑resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. Xofigo is available as a ready to use solution for injection in a 6 mL vial (corresponding to a total activity of 6.6 MBq per vial) in packs of 1’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629